Physician profile
Danielle Forry
NPI 1447899125
$3,407.13
in general payments reported to CMS, 2019-2025
26 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.77 · 2022: $159 · 2023: $2,180 · 2024: $844 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,232.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $416.56 | 2022-2025 | Entyvio, Gattex |
| Celgene Corporation | $318.40 | 2022-2024 | Zeposia |
| Genzyme Corporation | $291.56 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $244.76 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $213.65 | 2023-2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.37 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $131.66 | 2023-2024 | |
| Janssen Biotech, INC. | $126.95 | 2023-2024 | Stelara, Simponi Aria, Remicade |
| Intercept Pharmaceuticals, INC. | $104.44 | 2022-2023 | Ocaliva |
| Qol Medical, LLC | $98.18 | 2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $75.75 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $63.00 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $46.51 | 2024 | Iqirvo |
| Gilead Sciences, INC. | $32.83 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $31.21 | 2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $30.26 | 2023 | Rebyota |
| Mallinckrodt Hospital Products INC. | $27.00 | 2024 | Terlivaz |
| Celltrion USA INC. | $26.50 | 2025 | Vegzelma |
| Alexion Pharmaceuticals, INC. | $24.61 | 2023 | |
| Fresenius Kabi USA, LLC | $24.06 | 2023 | Idacio |
| Glaxosmithkline, LLC. | $15.77 | 2021 | |
| Braintree Laboratories, INC. | $15.64 | 2023 | Sutab |
| Lilly USA, LLC | $14.63 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $12.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.66 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Forry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.